, /PRNewswire/ -- Douglas Pharmaceuticals, largest pharmaceutical company, is pleased to announce that results from their recent trial, "Randomised Placebo-Controlled Phase 2 Study of Extended-Release Ketamine Tablets (R-107) for Treatment-Resistant Depression", also known as the BEDROC study, have just been published by the leading scientific journal Nature Medicine. Douglas Pharmaceuticals' Chief Scientific Officer, Dr , commented, "We're pleased that the quality and design of the study, as well as the significance of the findings have been recognised and are now being shared with industry peers. Should R-107 perform in Phase 3 studies as in the BEDROC study this would be a life-changing medication for many individuals who suffer from Treatment-Resistant Depression (TRD), and one that could be taken safely at-home.
" The BEDROC study enrolled patients with TRD who had failed two or more antidepressants in the current period of depression. Patients responded rapidly to R-107 during the daily dose induction phase of BEDROC and around 73% (168/231) of patients were responders after 1 week. This response rate is comparable to results achieved with off-label IV ketamine treated TRD patients but without undesirable dissociation (spacing out).
R-107 shows promise to be a rapid acting, convenient and accessible form of ketamine. Dr Surman acknowledged the valuable contributions made by Douglas' Product Development Team, the investigators involved, and Professor , MD, University of O.
